The incidence of esophageal adenocarcinoma (EAC) has increased more than six-fold over the past three decades and continues to rise in the Western world. Diagnosis at an advanced stage and poor prognosis make EAC one of the most lethal diseases, thus urging further research to better understand the pathophysiology of the disease.
Both cell-line-based in vitro and in vivo xenograft models have been used to study the pathophysiology of EAC. However, these cell-line based models do not properly reflect the heterogeneity of the tumor. Therefore, alternative models that resemble human cancer more closely are being developed to help in understanding the molecular pathogenesis of EAC and facilitate the development of novel anticancer interventions.
The aim of this Research Topic is to cover recent advances in in vivo models for esophageal adenocarcinoma (EAC). Areas to be covered in this Research Topic may include, but are not limited to:
• Development of genetically engineered EAC mouse models
• Patient-derived xenografts (PDX) and organoids (PDO)
• Application of PDX and PDO models to model human cancer biology, chemo-resistance, and their utility in testing novel therapeutics
• Chemical induction and other experimental EAC models
The incidence of esophageal adenocarcinoma (EAC) has increased more than six-fold over the past three decades and continues to rise in the Western world. Diagnosis at an advanced stage and poor prognosis make EAC one of the most lethal diseases, thus urging further research to better understand the pathophysiology of the disease.
Both cell-line-based in vitro and in vivo xenograft models have been used to study the pathophysiology of EAC. However, these cell-line based models do not properly reflect the heterogeneity of the tumor. Therefore, alternative models that resemble human cancer more closely are being developed to help in understanding the molecular pathogenesis of EAC and facilitate the development of novel anticancer interventions.
The aim of this Research Topic is to cover recent advances in in vivo models for esophageal adenocarcinoma (EAC). Areas to be covered in this Research Topic may include, but are not limited to:
• Development of genetically engineered EAC mouse models
• Patient-derived xenografts (PDX) and organoids (PDO)
• Application of PDX and PDO models to model human cancer biology, chemo-resistance, and their utility in testing novel therapeutics
• Chemical induction and other experimental EAC models